Foghorn Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
106
- Stock Symbol
-
FHTX
- Share Price
-
$1.73
- (As of Friday Closing)
Foghorn Therapeutics General Information
Description
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Contact Information
Website
www.foghorntx.comCorporate Office
- 99 Coolidge Avenue
- Suite 500
- Watertown, MA 02472
- United States
Corporate Office
- 99 Coolidge Avenue
- Suite 500
- Watertown, MA 02472
- United States
Foghorn Therapeutics Timeline
Foghorn Therapeutics Stock Performance
As of 20-Nov-2026, Foghorn Therapeutics’s stock price is $1.73. Its current market cap is $103M with 60M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.73 | $1.78 | $1.66 - $7.61 | $103M | 60M | 840K | $0.10 |
Foghorn Therapeutics Financials Summary
As of 30-Sep-2026, Foghorn Therapeutics has a trailing 12-month revenue of $112M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 87,526 | 147,628 | 34,073 | 59,494 |
| Revenue | 112,129 | 30,909 | 22,602 | 34,155 |
| EBITDA | 4,315 | (79,696) | (95,400) | (101,575) |
| Net Income | 9,420 | (74,283) | (86,620) | (98,426) |
| Total Assets | 190,952 | 198,103 | 283,982 | 285,916 |
| Total Debt | 43,868 | 41,270 | 37,131 | 45,073 |
Foghorn Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Foghorn Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Foghorn Therapeutics Comparisons
Industry
Financing
Details
Foghorn Therapeutics Competitors (10)
One of Foghorn Therapeutics’s 10 competitors is Kymera Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| C4 Therapeutics | Formerly VC-backed | Watertown, MA |
Foghorn Therapeutics Patents
Foghorn Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026090300-A1 | Compounds and uses thereof | Pending | 23-Oct-2024 | ||
| WO-2026090317-A1 | Compounds and uses thereof | Pending | 23-Oct-2024 | ||
| WO-2026090330-A1 | Compounds and uses thereof | Pending | 23-Oct-2024 | ||
| WO-2026090340-A1 | Methods of treating metabolic disorders | Pending | 23-Oct-2024 | ||
| WO-2026085172-A1 | Combination therapy for treating hematological cancers | Pending | 16-Oct-2024 | A61K31/5377 |
Foghorn Therapeutics Signals
Foghorn Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Foghorn Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Foghorn Therapeutics FAQs
-
When was Foghorn Therapeutics founded?
Foghorn Therapeutics was founded in 2015.
-
Where is Foghorn Therapeutics headquartered?
Foghorn Therapeutics is headquartered in Watertown, MA.
-
What is the size of Foghorn Therapeutics?
Foghorn Therapeutics has 106 total employees.
-
What industry is Foghorn Therapeutics in?
Foghorn Therapeutics’s primary industry is Drug Discovery.
-
Is Foghorn Therapeutics a private or public company?
Foghorn Therapeutics is a Public company.
-
What is Foghorn Therapeutics’s stock symbol?
The ticker symbol for Foghorn Therapeutics is FHTX.
-
What is the current stock price of Foghorn Therapeutics?
As of 20-Nov-2026 the stock price of Foghorn Therapeutics is $1.73.
-
What is the current market cap of Foghorn Therapeutics?
The current market capitalization of Foghorn Therapeutics is $103M.
-
What is Foghorn Therapeutics’s current revenue?
The trailing twelve month revenue for Foghorn Therapeutics is $112M.
-
Who are Foghorn Therapeutics’s competitors?
Kymera Therapeutics, Arvinas, Nurix Therapeutics, Vividion Therapeutics, and C4 Therapeutics are some of the 10 competitors of Foghorn Therapeutics.
-
What is Foghorn Therapeutics’s annual earnings per share (EPS)?
Foghorn Therapeutics’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process